PTK2 and non-small cell lung carcinoma: Interestingly, co-treatment of NSCLC cells with FAK and Hsp90 inhibitors reduces the Erk1⁄2-mediated feedback survival signaling below that of Hsp90 inhibitors alone, in part, explaining the enhanced effect by the combination.